The first time a patient described it as *”not just losing weight—it’s like my brain forgot how to crave food,”* the medical community took notice. Semaglutide, the GLP-1 receptor agonist behind the meteoric rise of brands like Ozempic and Wegovy, wasn’t just another weight-loss drug—it was a paradigm shift. For decades, diets and pills had […]